- Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, Muneer A. J Sex Med. 2018 Apr; 15(4):430-457. Return to content
Nebido® (testosterone undecanoate) is contraindicated in men with androgen-dependent carcinoma of the prostate. Careful an regular monitoring of the prostate gland must be performed in accordance with recommended methods (digital rectal examination and serum PSA measurement) in patients receiving testosterone therapy, especially in elderly and at risk patients. Local guidelines for safety monitoring should be taken into consideration. Please refer to the Summary of Product Characteristics for full details http://www.bayer.co.uk/en/businesses/bayer-healthcare/bayer-healthcare-pharma/our-products.